Overview

AGN-199201 for the Treatment of Erythema With Rosacea

Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
0
Participant gender:
All
Summary
This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Criteria
Inclusion Criteria:

- Redness of the skin caused by rosacea

Exclusion Criteria:

- ≥3 inflammatory lesions

- Laser light-source or other energy based therapy in the last 6 months

- Any prescription or over the counter product for the treatment of acne or rosacea in
the last 14 days